MATE™: NEXT GENERATION ANTIBODY CONJUGATION TECHNOLOGY

Multimodal Antibody Therapy Enhancers or (MATE™) are a next-generation antibody conjugation technology that enables site-directed pairing with off-the-shelf therapeutic monoclonal antibodies (mAbs), or therapeutic commercial immunoglobulin (IG) pooled from donors.

Biohaven MATE - Multimodal Antibody Therapy Enhancers